Merrill: Confidence...
Health Care: Drugs
Santarus Inc. (SNTS: NASDAQ)
$22.30 0.20 | 0.90%
05/21/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 22.10 |
| 52 Week High | 22.49 |
| 52 Week Low | 4.82 |
| Avg. Daily Vol. (Mil) | 1.31 |
| Beta (3 year) | 1.80 |
| Share Related Items | |
| Mkt Cap (Mil) | 1,435.05 |
| Shares Out (Mil) | 64.93 |
| Float (Mil) | 55.12 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.10 |
| Current Ratio | 2.40 |
| LT Debt/ Equity | 0.09 |
| Total Debt / Equity | 0.09 |
| Valuation Ratios | |
| Price Earnings | 43.30 |
| Price/Sales | 5.71 |
| Price/Book | 13.40 |
| Price/Cash Flow | 33.40 |
| Per Share Data | |
| Earnings | 0.51 |
| Sales | 3.87 |
| Book Value | 1.65 |
| Cash Flow | 0.66 |
| Business Summary | |
|---|---|
| Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. | |
| General Information | |
| 3611 Valley Centre Drive
Suite 400 San Diego, CA 92130 |
|
| www.santarus.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 290 | |
| CEO: Gerald T. Proehl | |
| Short Interest | |
| Current Month (Mil) | 2.73 |
| Previous Month (Mil) | 3.73 |
| Short Interest Ratio (Days) | 2.40 |
| Management Effectiveness | |
| Return on Equity | 34.20 |
| Return on Assets | 19.30 |
| Return on Investments | 31.30 |
| Profitability | |
| Gross Margin | 67.60 |
| EBIT Margin | 15.50 |
| Profit Margin | 14.60 |
Portfolios with SNTS
- Portfolio NameUser Type
- UserWatch
- ContributorStocks Under-$10 Setting Up...
- ContributorDrugs Facing FDA Approval i...
- ContributorBreakout Stocks Of The Week...
- UserRogers BioMed
- ContributorStocks At New 52-Week Highs...
- UserJust Learning ao926
- UserJust Learning
- ContributorDollar Store
- Userbetterlatethannever
Latest SNTS Headlines from TheStreet
- Dow Closes at Record High 03.05.13 | 04:03 pm
- Cramer's 'Mad Money' Recap: The Bullish Facts 01.17.13 | 08:01 pm
- 5 Stocks Insiders are Buying This Week 12.26.12 | 12:12 pm
- Top Insider Trades: LMCA, ST, SNTS, BEAV 12.20.12 | 01:12 pm
- Stocks Under $5: Discount Drug Name
11.29.12 | 06:11 am - 5 Under-$10 Stocks Set to Trade Higher in November 11.08.12 | 01:11 pm
- Santarus Inc. Stock Upgraded (SNTS) 08.27.12 | 05:08 am
- Santarus' CEO Discusses Q2 2012 Results - Earnings Call Transcript 08.07.12 | 09:08 pm
- Santarus Reaches New 52-Week High (SNTS) 06.12.12 | 04:06 pm
- Santarus Stock Falls On Unusually High Volume (SNTS) 05.30.12 | 04:05 pm
Press Releases for SNTS
- Santarus Announces Publication In Gut Of Results From UCERIS (budesonide) European Pivotal Clinical Study - Business Wire 03.18.13 | 07:03 am
- Santarus And VeroScience Announce Publication Of AACE Expert Panel Recommendations For CYCLOSET® (bromocriptine Mesylate) For The Management Of Type 2 Diabetes - Business Wire 03.06.13 | 07:03 am
- Santarus Reports Fourth Quarter And Full Year 2012 Financial Results - Business Wire 03.04.13 | 04:03 pm
- Santarus To Present At March Investment Conferences - Business Wire 02.27.13 | 07:02 am
- Santarus To Hold Fourth Quarter And Full Year 2012 Financial Results Conference Call On March 4 - Business Wire 02.19.13 | 07:02 am
- Santarus Announces Commercial Launch Of UCERIS (budesonide) Extended Release Tablets - Business Wire 02.14.13 | 07:02 am
- Santarus To Present At Leerink Swann Global Healthcare Conference - Business Wire 02.06.13 | 07:02 am
- Santarus And VeroScience Announce Publication Of Positive Data From Pivotal CYCLOSET® (bromocriptine Mesylate) Efficacy Study - Business Wire 01.23.13 | 07:01 am
- Santarus Receives FDA Approval Of UCERIS (Budesonide) For The Induction Of Remission In Patients With Active, Mild To Moderate Ulcerative Colitis - Business Wire 01.14.13 | 07:01 pm
- Santarus And VeroScience Announce Publication Of New Analysis Of CYCLOSET (bromocriptine Mesylate) Cardiovascular Data In The Journal Of The American Heart Association - Business Wire 11.13.12 | 07:11 am
Partner Headlines for SNTS
- FDA Panel Kills Sefelsa, Creates Buying Opportunity In Depomed Stock - Seeking Alpha 03.05.13 | 09:03 am
- Roth Capital's Henry Sees Upcoming FDA Panel For Depomed's Sefelsa As A Coin Flip - Seeking Alpha 03.01.13 | 05:03 pm
- Serada Approval Presents Big Upside To Depomed - Seeking Alpha 01.30.13 | 09:01 am
- Three Compelling Biopharma Stocks For 2013 - Seeking Alpha 12.26.12 | 09:12 am
- 5 BioPharmas To Watch For Wednesday, September 5 - Seeking Alpha 09.05.12 | 09:09 am
- Santarus - Momentum - Zacks 07.18.12 | 01:07 am
- Verizon and 2 Stocks BREAKING 52-Week Highs - Wall St. Cheat Sheet 06.13.12 | 12:06 pm
- Most Volatile Stocks on Earnings Report Days - Seeking Alpha 01.07.11 | 07:01 pm
- UPDATE 1-Santarus files for approval of anti-swelling drug - Reuters 12.28.10 | 09:12 am
- Santarus' Q3 Loss: The Rough Path to Recovery - Seeking Alpha 11.09.10 | 09:11 am
